

medmix Beauty: Micro-bristle applicator pureIDENTITY

Strategy

Platform for growth

Our heritage is one of designing, developing and manufacturing high-precision delivery devices for the healthcare and consumer & industrial markets. Building on our core competence of plastics injection molding and our in-depth automation expertise, we have expanded from Industry applications into the Dental, Drug Delivery, Surgery and Beauty segments. In each of our segments, we have identified profitable and resilient niche markets with strong customer relationships, and long-term growth, supported by global trends such as a growing middle class, an aging population, increased urbanization, self-administered treatment and sustainability.

High-precision delivery devices in attractive end markets

Niche leader	Highly protected	Platform for growth	
 Attractive and resilient B2B niche markets Exciting underlying macro growth trends Fragmented competition landscape 	 High level of regulation High IP protection through innovation High share of repeat business 	 Long-standing customer relationships Legacy of standard-setting innovation Technology and quality leader 	
🙀 medmix			
Leverage trends acrossScale technology and in	J	ergies across our infrastructure lent product development	

We believe that we benefit from long-standing customer relationships and positive macro trends in the end markets we address, which we expect to provide us with significant growth opportunities as we expand our target markets.

Macro trends

Main segment trends

لکتیکا Growing middle class	 Emerging markets shift away from hand- to device-mixing Trend to unit-dose to avoid cross contamination Growing number of dentists in emerging markets
کے Aging population	 Trend towards self-injection at home Growth in biosimilars for self-administration Increasing number of biologics in pipelines
Urbanization	 Increasing use of bone cement for trauma More biomaterials in wound healing reducing post-op risks
Healthcare at home	 Shift to adhesive bonding due to cost and time savings Innovative adhesives and sealants expanding application areas
یک Sustainability	 Increasing customization and premiumization – even for mass market products Demand for sustainable materials and local supply chains Indie and mid-sized brands demanding full-service offering

Innovative, trend-oriented product development

We are a lean, innovative and customer-centric solutions provider and aim to further exploit our strategic setup across all segments by leveraging our industrial DNA – creating synergies and scale through knowledge sharing across the medmix group.

In particular, we strive to leverage early trends and best practices across segments. In this context, we were able to further advance innovation, with a sustainability mindset, in all segments, as part of the medmix DNA. Especially in the Beauty segment further sustainability achievements were made as medmix was awarded the EcoVadis Platinum Medal for Sustainability, thus placing our Beauty business in the top 1% of the companies rated within this industry. Not only were we the first company in the Beauty industry to achieve this distinction, we also have been able to maintain it for the third year in a row. Additionally, we cemented medmix as a pioneer in the Industry segment as our sustainable EcopaCC[™] and greenLine[™] product offerings have been favorably received by the market. We are committed to reducing the CO₂ footprint of our whole supply chain in the coming years, providing our customers with sustainable solutions.

M&A focus

We have an established M&A track record over the past 16 years, by concentrating on acquiring companies that ensure a strong strategic fit with our existing product offering globally. Our M&A strategy comprises two pillars:

- For Healthcare, we aim to focus on expanding our core product portfolio and enter into adjacencies
- For Consumer & Industry, our focus will be local-for-local acquisitions in China to take advantage of the growth in the local markets

During 2022, we acquired the plastics business of Universal de Suministros, S.L., Valencia, Spain, enabling medmix to rapidly scale up production for our Industry segment, replacing the capacity from our closed plant in Poland and accommodating the growing demand from European and global customers.

"Our long-standing M&A expertise, demonstrated over the past 16 years through strategic company acquisitions, reinforces our dedication to expanding our product offering globally."

Jennifer Dean

Chief Financial Officer



One year as an independent company

We advanced our spin-off and closed 2022 as our first year in full independence. We have served the needs of our customers without a transitional impact from the spin-off. The listing on the Swiss stock exchange has helped medmix to sharpen the company's profile as an emerging healthcare business, increasing our visibility both to investors and customers. It also contributed to our profile as an employer, helping to attract talent from around the world.